CASE REPORT Open Access

POLG1 mutations and stroke like episodes: a distinct clinical entity rather than an atypical MELAS syndrome

Antonella Cheldi1, Dario Ronchi2, Andreina Bordoni2, Bianca Bordo1, Silvia Lanfranconi2, Maria Grazia Bellotti1, Stefania Corti2, Valeria Lucchini3, Monica Sciacco3, Maurizio Moggio3, Pierluigi Baron2, Giacomo Pietro Comi2, Antonio Colombo1, Anna Bersano4\*and on behalf of Lombardia GENS collaborators

Abstract

Background: *POLG1* mutations have been associated with MELAS-like phenotypes. However given several clinical differences it is unknown whether *POLG1* mutations are possible causes of MELAS or give raise to a distinct clinical and genetic entity, named *POLG1*-associated encephalopathy.

Case presentation: We describe a 74 years old man carrying *POLG1* mutations presenting with strokes, myopathy and ragged red fibers with some atypical aspects for MELAS such as late onset, lack of cerebral calcification and presence of frontal and occipital MRI lesions better consistent with the POLG associated-encephalopathy spectrum.

Conclusion: The lack of available data hampers a definite diagnosis in our patient as well as makes it difficult to compare MELAS, which is a clearly defined clinical syndrome, with *POLG1*-associated encephalopathy, which is so far a purely molecularly defined syndrome with a quite heterogeneous clinical picture. However, the present report contributes to expand the phenotypic spectrum of *POLG1* mutations underlining the importance of searching *POLG1* mutations in patients with mitochondrial signs and MELAS like phenotypes but negative for common mtDNA mutations.

Keywords: POLG1, MELAS, Red-ragged fibers, Stroke-like

# Background

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome is a pheno- typically and genetically heterogeneous mitochondrial dis- order. Stroke-like episodes, which are usually transient and not-disabling, represent the clinical hallmarks. Additional features include seizures, cognitive decline, psychosis, lactic acidosis, migraine, visual impairment, hearing loss, short stature, diabetes and myopathy. MRI shows hyperintensi- ties on T2-weighted and DWI sequences mostly over the temporal, parietal and occipital regions, not confined to a vascular territory. Muscle biopsy typically shows ragged- red and COX-negative fibers, SDH hyperreactivity and, at ultrastructural level, abnormally shaped mitochondria with

\* Correspondence: [anna.bersano@gmail.com](mailto:anna.bersano@gmail.com)

4Cerebrovascular Unit, IRCCS Foundation Neurological Institute ‘C.Besta’, Via Celoria 23, 20135 Milan, Italy

Full list of author information is available at the end of the article

paracristalline inclusions. MELAS results in 80% of cases from a point mutation, m.3243A>G in the mitochondrial tRNALeu(UUR) gene (MTTL1) [[1](#_bookmark2),[2](#_bookmark2)]. Other mitochondrial DNA (mtDNA) mutations in *MTTL1* gene and other transfer RNA genes (*MTTF*, *MTTV*, *MTTQ*) as well as mutations in other subunits of complex 1 such as MTND1, MTND5 and MTND6 have been also identified as cause of MELAS [[3-6].](#_bookmark2) Indeed, mutations in nuclear genes leading to secondary mtDNA changes (depletions and multiple deletions), have been described as emerging causes of MELAS [[7]](#_bookmark2). Recently, Deschauer et al. described a patient showing stroke-like episodes and a right occipital lesion, headache, seizures, elevated CSF lactate, ragged–red fibers and carrying heterozygous mutations in mtDNA polymer- ase gene (*POLG1*) arguing that MELAS could be included in *POLG1* spectrum phenotype [[7](#_bookmark2)]. *POLG1* mutations were described, so far, in families with autosomal dominant and recessive chronic progressive external ophthalmoplegia



© 2013 Cheldi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License [(http://creativecommons.org/licenses/by/2.0),](http://creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



(PEO), Alpers syndrome, parkinsonism, optic neuritis and late onset ataxia [[8,9]](#_bookmark2). We previously reported a cohort of 67 patients affected by myopathy with or without PEO, in which 19.4% of patients carried *POLG1* mutations [[10](#_bookmark3)]. Herein, we report the 2-year neurological follow up of one of these patients disclosing over time a clinical phenotype highly consistent with MELAS.

# Case presentation

Patient’s history

A 74 year old man was admitted to the Neurological Unit of Desio Hospital in September 2004 for sudden onset of a speech disorder and left side weakness. Over the past ten years he developed a progressive bilateral ptosis, hear- ing loss and difficulties in swallowing. For these symptoms he was hospitalized in 1996 elsewhere. The neurological examination performed at that time revealed bilateral pto- sis, bilateral hearing loss and mild dysphagia. The neuro- physiological examination, performed in 1996, revealed a myopathic pattern. However, at that time the patient refused any further investigation including muscle biopsy. The remaining patient’s past history was unremarkable. In particular, except for a mild increase in cholesterol levels, cerebrovascular risk factors were absent. Family history was negative for muscular disorders, stroke, hearing loss, diabetes, short stature, headache, mental retardation or dementia. Neurological examination, performed on ad- mission in 2004, revealed bilateral ptosis and severe ophthalmoparesis, hearing loss, dysarthria, left facial nerve palsy and mild left side hemiparesis. Acute phase NIHSS score was 4. Fatigability and myotonic phenomena were absent. Acute phase cerebral CT scan was negative for acute ischemic lesions. Cerebral MRI, performed two days later, showed a right pre-rolandic hyperintensity on T2- weighted sequence, not confined to a specific vascular territory, with a slight enhancement after gadolinium, consistent with an acute ischaemic lesion. Other bilateral focal hyperintensities, mostly in the posterior circulation territory (cerebellar bilateral, left temporo-occipital and frontal) consistent with stabilized ischaemic lesions, were also found (Figure [1)](#_bookmark0). Biochemistry was normal except for increased level of serum creatine kinase (189→643, n.v 38–174 U/l). Inflammatory and autoimmune markers were normal as well as lactate serum level (1,7; n.v 0.5- 1.8 mmol/l). Electrocardiogram, echocardiography and abdominal ultrasonography were negative. Audiometry revealed a moderate sensorimotor bilateral hypoacusia. Ophthalmological examination, including fluoroangiogra- phy, excluded a pigmentary retinopathy. Electroencephal- ography was normal too. Neurophysiological examination demonstrated myopathic signs in frontal, masseters, orbi- cularis oculi and mouth muscles without denervation and normal findings in the other examined muscles (right bi- ceps, triceps, interosseous and left and right quadriceps,

tibialis anterior, medial gemellus). No signs of polyneurop- athy were detected. Ticlopidine 250 mg twice daily was started. Left hemiparesis resolved completely within 7 days. During the following years a progressive worsening of ptosis, ophthalmoparesis, hearing loss and dysphagia was observed. Cognitive impairment was not detected at MMSE. Headache and seizures were not referred too. In November 2008 the patient was hospitalized again for a sudden onset of aphasia. No other new-onset neurological symptoms were referred. The neurological examination performed at that time showed global aphasia and a right hemiparesis with right Babinski sign. The NIHSS score was 4. Residual signs such as severe bilateral ptosis, bilat- eral opthalmoparesis, bilateral hearing loss, dysarthria, solid food dysphagia were unchanged. Fatigability, cerebel- lar ataxia or sensitive deficits were absent. Biochemistry, echocardiography, epiaortic vessel Doppler ultrasound were normal. Cerebral CT scan performed in the acute phase was unmodified in comparison to the previous ones. Cerebral MRI at day 3 demonstrated a small cortical- subcortical left temporo-occipital lesion with DWI re- striction (Figure [1)](#_bookmark0). The strength deficit resolved in a few days whereas a language rehabilitation was necessary. Aphasia progressively recovered and was not present at the three months follow-up. The patient continued to as- sume ticlopidine.

Genetic analysis

Total DNA was extracted from peripheral blood and muscle. PCR-RFLP analysis did not reveal m.3243A>G mutation. Southern blot analysis of muscle mtDNA [[11]](#_bookmark3) revealed the presence of several bands compatible with mtDNA multiple deletions (Figure [2).](#_bookmark1) A specific PCR assay identified mtDNA multiple deletions using two primers (forward 7440–7465 and reverse complement 16135–16110) and the following amplification protocol: an initial denaturation at 94°C for 2 min, followed by 25 cycles (94°C for 30 s, 55°C for 30 s, and 68°C for 90 s) and a final extension for 2 min at 72°C (Platinum HiFi Taq Polymerase by Invitrogen, Carlsbad, CA). The entire coding sequence of POLG1 gene (NM\_002693.1) was PCR-amplified and directly sequenced disclosing the presence of three heterozygous variants: the c.752C>T (exon 3, p.T251I), c.1760C>T (exon 10, p.P587L) and c.3556G>C (exon 22, p.D1186H). We did not test any other family member for POLG mutations since parents are not alive and siblings are not available. Both the mutations p.T251I and p.P587L were reported several times in subjects showing multiple clinical phenotypes, according to the Human DNA Polymerase Gamma Muta- tion Database (<http://tools.niehs.nih.gov/polg/>). The mis- sense mutation c.3556G>C was not listed in the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) as well as in the POLG mutation database and it was not

Figure 1 A-D: Skeletal muscle biopsy showing one ragged red fiber with histological methods (A-B: H&E, 10X ; B: GT, 40X). Histochemical reactions for COX (C, 10X) and COX-SDH (D, 10X) in cross serial sections show lack of COX activity in several skeletal muscle fibers (C), many of which also show increased SDH activity (D).E-H: Axial T2-weighted cerebral MRI sequences showing a cortico-subcortical fronto- parietal hyperintensity with restricted diffusion (not shown) consistent with acute ischaemic lesion and bilateral old ischaemic lesions in the right occipital and left temporal lobe.





Figure 2 Molecular analysis of muscle-derived mitochondrial DNA. Southern blot (A) and PCR assay (B) showing the accumulation of multiple deletions in patient’s tissue.

found in more than 200 Italian healthy controls. The affected residue (position 1186) is evolutionarily con- served across species. Three software programs were used to predict the overall severity of this variant. According PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT (Sorting Intolerant From Tolerant, [http://sift.bii.a-star.](http://sift.bii.a-star.edu.sg/) [edu.sg](http://sift.bii.a-star.edu.sg/)/) and PMut (<http://mmb.pcb.ub.es/PMut/>), the p. D1186H change is predicted to be highly deleterious.

Skeletal muscle and nerve histopathology

In 2004 the patient underwent a left biceps skeletal muscle biopsy. Cryostatic cross sections were processed according to standard histological and histochemical techniques including Haematoxylin & Eosin (H&E), Gomori Trichrome (GT), Cytochrome c Oxidase (COX), Succinate Dehydrogenase (SDH) and double reaction for COX and SDH [[12].](#_bookmark3) Electron microscopy studies were performed as described [[13].](#_bookmark3)

Histological examination of muscle specimen showed slight fiber size variability, some nuclear centralizations and several fiber splittings along with a consistent num- ber (n=10) of ragged red fibers (RRF). Necrosis was observed in a few fibers. Histochemically, several fibers were Cytochrome c Oxidase (COX)-negative, many of these fibers were also intensely SDH-positive (Figure [1).](#_bookmark0)

DNA sample and muscle biopsy were collected after obtaining patient informed consent according to the local ethics and privacy and human subjects’ protection regulations and were taken as part of standard patient care.

# Conclusion

The human mitochondrial genome is replicated by the DNA polymerase γ, pol γ, which is encoded by *POLG1*, which is a 23 exons nuclear gene located on chro- mosome 15q25. Heterozygous and homozygous *POLG1* mutations have been typically associated with heteroge- neous and severe clinical phenotypes of PEO, both in autosomal dominant or recessive form. They can also result in adult onset cerebellar ataxia with mtDNA mul- tiple deletions and Alpers syndrome, an autosomal re- cessive hepatocerebral disease characterized by severe developmental delay, intractable seizures, liver failure and death in childhood. Moreover, throughout the years a wide spectrum of clinical findings including parkinson- ism, neuropathy, optic neuritis, psychiatric disorders has been described in *POLG1* mutations carriers [[12,14-19].](#_bookmark3) Deschauer et al. 2007 described a patient presenting with occipital seizures and residual homonymous hemi- anopsia, headache and ataxia and carrying two heterozy- gous *POLG1* mutations [[7].](#_bookmark2) The presence of occipital symptoms and lesions, interpreted as stroke-like epi- sodes, together with elevated CSF lactate and ragged red fibers, posed the suspicion of MELAS, raising the ques- tion whether *POLG1* mutations could be associated with a MELAS like phenotype [[7,20].](#_bookmark3) However, given several clinical differences between *POLG1* patient characteris- tics and MELAS, it has been supposed that, despite some overlapping symptoms, *POLG1* represent a distinct clinical and genetic entity. POLG-associated encephalop- athy has been postulated to give rise to a distinct pheno- type, including variable age at onset, either recessive or dominant inheritance pattern and peculiar neuroimaging

findings characterized by predominant posterior ische- mic lesions and lack of cerebral calcification [[21].](#_bookmark3)

Our case had some atypical aspects for MELAS such as late onset, lack of cerebral calcification and presence of frontal and occipital MRI lesions better consistent with the POLG associated-encephalopathy spectrum. However, it is difficult to assess with certainty whether our patient could be classified as MELAS-like or POLG- associated encephalopathy. Moreover, although the pa- tient did not present any vascular risk factor, given the elderly age a co-incidence between a POLG myopathy and a cerebrovascular disease can not be excluded at all. However, it is difficult to compare MELAS, which is a clearly defined clinical syndrome, with *POLG1*-associated encephalopathy, which is so far a purely molecularly defined syndrome with a quite heterogeneous clinical pic- ture. In addition, although 140 POLG mutations have been described in patients with symptoms that suggest mitochondrial disease, most of mutations are reported in heterozygous in whom each POLG allele can be one or more different mutations and only few of these has been replicated in not related families. This makes difficult a clear definition of phenotype and in providing evidence of

the disease causing nature of these mutations [[22](#_bookmark3)].

Our patient harboured the haplotype p.[T251I P587L] in combination with D1186H located in polymerase do- main. The haplotype T251I and P587L has been already described but it is currently not possible to know whether T251I or P587L is the primary pathogenic allele or whether both mutations are necessary to cause dis- ease. Nevertheless both variants have also been reported in trans one each other in affected subjects. Notably both P587 and D1186 residues are located in the DNA binding channel of POLG enzyme. Thus, the substitu- tions found in our patient could be consistent with a reduced DNA binding capacity.

However, given the lack of available data, the imple- mentation of existing databases ([http://tools.niehs.nih.gov/](http://tools.niehs.nih.gov/polg/) [polg/](http://tools.niehs.nih.gov/polg/)) including single unpublished observations from clinicians, is necessary to determine allelic frequencies of the myriad of *POLG1* mutations [[22,23](#_bookmark3)]. Ongoing studies on biochemical measurements of polymerase activity and in vivo measurement of mitochondrial dysfunction will provide further issue on their pathogenic role.

The present report contributes to expand the pheno- typic spectrum of *POLG1* mutations underlining the im- portance of searching *POLG1* mutations in patients with mitochondrial signs and MELAS like phenotypes but negative for common mtDNA mutations.

# Informed consent

Written informed consent was obtained from the patient for the publication of this case report and any accom- panying images.

Competing interest

All the authors disclose any conflicts of interest including any financial (grant or fundings), personal or other relationships with other people or organizations within three years of beginning the work submitted that could inappropriately influence or bias their work.

Authors’ contributions

AC, BB, MGB have made substantial contributions to case conception and design, acquisition of data and have been directly involved in drafting and revising the manuscript. AB, MS, VL, MM, AC have made substantial contributions to genetic, biochemical and hystological analyses and interpretation of data. DR, SL, SL PL, GPC, AB (\*) have made substantial contributions case to conception and design, analysis and interpretation of data and have been directly involved in drafting and revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgement

We wish to thank ‘LOMBARDIA GENS’ network and project for their support. The existent network and the research grants of Regione Lombardia is gratefully acknowledged. The financial support of Associazione Amici del Centro Dino Ferrari, University of Milan, the Telethon project GTB07001, the Eurobiobank project QLTR-2001-02769 and R.F. 02.187 Criobanca Automatizzata di Materiale Biologico are gratefully acknowledged. Written consent was obtained from the patient for publication.

Author details

1Neurological Unit, Ospedale di Desio, Azienda Ospedaliera di Desio e Vimercate, Monza, Italy. 2Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milan 20122, Italy. 3Neuromuscular Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, University of Milan, Milan 20122, Italy. 4Cerebrovascular Unit, IRCCS Foundation Neurological Institute ‘C.Besta’, Via Celoria 23, 20135 Milan, Italy.

Received: 3 February 2012 Accepted: 3 January 2013

Published: 15 January 2013

References

1. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. *Ann Neurol* 1984, 16:481–488.
2. Goto Y, Nonaka I, Horai S: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 1990, 348:651–653.
3. Di Mauro S, Schon EA: Mitochondrial respiratory-chain diseases. *N Engl J Med* 2003, 348:2656–68.
4. Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG: Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? *Ann Neurol* 2003, 53:128–132.
5. Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M: An mtDNA mutation, 14453G–>A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome. *Eur J Hum Genet* 2001, 9:805–809.
6. Kirby DM, McFarland R, Ohtake A, Dunning C, Ryan MT, Wilson C, Ketteridge D, Turnbull DM, Thorburn DR, Taylor RW: Mutations of the mitochondrial ND1 gene as a cause of MELAS. *J Med Genet* 2004, 41:784–789.
7. Deschauer M, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM, Zierz S, Taylor RW: MELAS associated with mutations in the *POLG1* gene. *Neurology* 2007, 68:1741–1742.
8. Horvath R, Hudson G, Ferrari G, Fütterer N, Ahola S, Lamantea E, Prokisch H, Lochmüller H, McFarland R, Ramesh V, Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, Udd B, Taylor RW, Turnbull D, Hanna M, Fialho D, Suomalainen A, Zeviani M, Chinnery PF: Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. *Brain* 2006, 129:1674–1684.
9. Echaniz-Laguna A, Chassagne M, de Sèze J, Mohr M, Clerc-Renaud P, Tranchant C, Mousson de Camaret B: *POLG1* variations presenting as multiple sclerosis. *Arch Neurol* 2010, 67:1140–1143.
10. Virgilio R, Ronchi D, Hadjigeorgiou GM, Bordoni A, Saladino F, Moggio M, Adobbati L, Kafetsouli D, Tsironi E, Previtali S, Papadimitriou A, Bresolin N, Comi GP: Novel Twinkle (PEO1) gene mutations in mendelian progressive external ophthalmoplegia. *J Neurol* 2008, 255:1384–1391.
11. Zeviani M, Gellera C, Pannacci M, Uziel G, Prelle A, Servidei S, DiDonato S: Tissue distribution and transmission of mitochondrial DNA deletions in mitochondrial myopathies. *Ann Neurol* 1990, 28:94–97.
12. Davidzon G, Mancuso M, Ferraris S, Quinzii C, Hirano M, Peters HL, Kirby D, Thorburn DR, DiMauro S: POLG mutations and Alpers syndrome. *Ann Neurol* 2005, 57:921–923.
13. Sciacco M, Prelle A, Comi GP, Napoli L, Battistel A, Bresolin N, Tancredi L, Lamperti C, Bordoni A, Fagiolari G, Ciscato P, Chiveri L, Perini MP, Fortunato F, Adobbati L, Messina S, Toscano A, Martinelli-Boneschi F, Papadimitriou A, Scarlato G, Moggio M: Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. *J Neurol* 2001, 248:778–788.
14. Van Goethem G, Dermaut B, Löfgren A, Martin JJ, Van Broeckhoven C: Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. *Nat Genet* 2001, 28:211–212.
15. Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, Rantamaki M, Goethem GV, Lofgren A, Hackman P, Paetau A, Kaakkola S, Majamaa K, Varilo T, Udd B, Kaariainen H, Bindoff LA, Suomalainen A: Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. *Am J Hum Genet* 2005, 77:430–441.
16. Del Bo R, Bordoni A, Sciacco M, Di Fonzo A, Galbiati S, Crimi M, Bresolin N, Comi GP: Remarkable infidelity of polymerase gammaA associated with mutations in *POLG1* exonuclease domain. *Neurology* 2003, 61:903–908.
17. Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, Papadimitriou A, Spelbrink H, Silvestri L, Casari G, Comi GP, Zeviani M: Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. *Ann Neurol* 2002, 52:211–219.
18. González-Vioque E, Blázquez A, Fernández-Moreira D, Bornstein B, Bautista J, Arpa J, Navarro C, Campos Y, Fernández-Moreno MA, Garesse R, Arenas J, Martín MA: Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population. *Arch Neurol* 2006, 63:107–111.
19. Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, Ferrari G, Aarseth JH, Bindoff LA: The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. *Brain* 2006, 129:1685–1692.
20. Tzoulis C, Bindoff LA: Melas associated with mutations in the *POLG1* gene.

*Neurology* 2008, 70:1054.

1. Tzoulis C, Neckelmann G, Mørk SJ, Engelsen BE, Viscomi C, Moen G, Ersland L, Zeviani M, Bindoff LA: Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. *Brain* 2010, 133:1428–1437.
2. Stumpf JD, Copeland WC: Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations. *Cell Mol Life Sci* 2011, 68:219–233.
3. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, DiMauro S, Rowland LP: Melas: an original case and clinical criteria for diagnosis. *Neuromuscul Disord* 1992, 2:125–135.

doi:10.1186/1471-2377-13-8

Cite this article as: Cheldi *et al.*: POLG1 mutations and stroke like episodes: a distinct clinical entity rather than an atypical MELAS syndrome. *BMC Neurology* 2013 13:8.



**Submit your next manuscript to BioMed Central and take full advantage of:**

* **Convenient online submission**
* **Thorough peer review**
* **No space constraints or color ﬁgure charges**
* **Immediate publication on acceptance**
* **Inclusion in PubMed, CAS, Scopus and Google Scholar**
* **Research which is freely available for redistribution**

Submit your manuscript at [www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)